CureVax, LLC logo

CureVax, LLC

CureVax, LLC, is an immunotherapy company dedicated to developing Viral oncolysate vaccine against melanoma. A viruslysed tumor cell vaccine is an active immunotherapeutic agent against tumors in mammals.

CureVax, LLC, is developing a recombinant, IL-2-secreting vaccinia virus-based, multivalent antigen retrieval platform using five proprietary patient derived melanoma cells.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://curevax.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
610 West 42nd St Apartment 55a,NY 10036
Brooklyn
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Under the Vaccine prepration method, tumor cells are removed from a mammal, the cells are cultured in a culture medium and infected with live vaccinia virus. Viral oncolysis occurs during incubation and the resulting viral oncolysate, after extraction, may be injected into mammals to stimulate the immune response mechanism.